Advanced Accelerator Applications announces that it has acquired 100% of IEL in newly issued AAA shares. The acquisition gives AAA its first direct presence in the UK and Ireland, expanding its existing services and expertise in nuclear medicine and providing it with an established sales and marketing platform.
The UK’s nuclear medicine market is one of the largest in Europe, with annual sales of more than €120 million. IEL generated sales of almost £6.77 million for the year ended 31 December 2013, up 58% on 2012.
As part of the transaction, IEL’s founding shareholders and top management will become shareholders in AAA, which demonstrates the commitment to continuity and the shared common views in terms of development and value creation.